Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1105059

registered interest
date	26/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Fatigue Syndrome: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	What recent progress has been made on the treatment of myalgic encephalomyelitis.
tabling member constituency	West Bromwich West
tabling member printed	Mr Adrian Bailey
uin	910043
answer	answer is ministerial correction date of answer 26/03/2019 answer text <p>In September 2017, the National Institute for Health and Care Excellence announced its plans for a full update to the existing clinical guideline on the diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) to ensure that treatment reflects the latest available evidence. The revised guideline will be published in 2020.</p><p>Since 2011, we have also invested £6 million into research into CFS/ME via the Medical Research Council and the National Institute for Health Research.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/03/2019 15:46:59 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	320 label Biography information for Mr Adrian Bailey

1064472

registered interest
date	20/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nusinersen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the planned timescale is for patients to access Spinraza treatment for muscular atrophy types 2 and 3.
tabling member constituency	West Bromwich West
tabling member printed	Mr Adrian Bailey
uin	224024
answer	answer is ministerial correction date of answer 28/02/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy, including types 2 and 3.</p><p> </p><p>NHS England and NICE have been in discussions with the manufacturer of Spinraza, Biogen, to explore whether there are commercial flexibilities that might enable NICE to recommend the drug as a clinically and cost effective use of NHS resources. Biogen has now submitted a revised submission for NICE’s independent Appraisal Committee to consider and a meeting has been arranged for 6 March 2019 to consider the recommendations. In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 224025 question first answered 28/02/2019 11:56:53 answering member 4067 label Biography information for Steve Brine
tabling member	320 label Biography information for Mr Adrian Bailey

1064473

registered interest
date	20/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nusinersen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress has been made on concluding a managed access treatment agreement for the use of Spinraza for patients with spinal muscular atrophy types 2 and 3.
tabling member constituency	West Bromwich West
tabling member printed	Mr Adrian Bailey
uin	224025
answer	answer is ministerial correction date of answer 28/02/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy, including types 2 and 3.</p><p> </p><p>NHS England and NICE have been in discussions with the manufacturer of Spinraza, Biogen, to explore whether there are commercial flexibilities that might enable NICE to recommend the drug as a clinically and cost effective use of NHS resources. Biogen has now submitted a revised submission for NICE’s independent Appraisal Committee to consider and a meeting has been arranged for 6 March 2019 to consider the recommendations. In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 224024 question first answered 28/02/2019 11:56:53 answering member 4067 label Biography information for Steve Brine
tabling member	320 label Biography information for Mr Adrian Bailey